K H Rand|T C Merigan - JoVE Visualize

Showing results (271-280 of 295) with videos related to

Pageof 30

Sort By:

Sexually Transmitted Diseases|January 1, 1991

Multicenter study of a single 500-mg dose of cefotaxime for treatment of uncomplicated gonorrheaF N Judson, L J Eron, F B Lutz, et al.

The New England Journal of Medicine|April 30, 1992

A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantationT C Merigan, D G Renlund, S Keay, et al.

Annals of Internal Medicine|November 1, 1984

Survival in chronic hepatitis B. An analysis of 379 patientsJ I Weissberg, L L Andres, C I Smith, et al.

Nature Medicine|July 1, 1996

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arraysM J Kozal, N Shah, N Shen, et al.

Journal of Virological Methods|December 1, 1987

Trifluorothymidine: potential non-invasive diagnosis of herpes simplex infection using 19F nuclear magnetic resonance in a murine hepatitis modelK H Rand, I Raad, A el Koussi, et al.

Blood|February 15, 1989

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferonS L Brown, R A Miller, S J Horning, et al.

Journal of Virology|May 1, 1987

Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responsesJ W Torseth, G H Cohen, R J Eisenberg, et al.

The Journal of Infectious Diseases|January 1, 1997

Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipientsL Rasmussen, C Hong, D Zipeto, et al.

Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)C M Gray, J Lawrence, J M Schapiro, et al.

The Journal of Infectious Diseases|June 1, 1996

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.

Pageof 30

Showing results (271-280 of 295) with videos related to

Sort By:

Pageof 30

Sexually Transmitted Diseases|January 1, 1991

Multicenter study of a single 500-mg dose of cefotaxime for treatment of uncomplicated gonorrheaF N Judson, L J Eron, F B Lutz, et al.

The New England Journal of Medicine|April 30, 1992

A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantationT C Merigan, D G Renlund, S Keay, et al.

Annals of Internal Medicine|November 1, 1984

Survival in chronic hepatitis B. An analysis of 379 patientsJ I Weissberg, L L Andres, C I Smith, et al.

Nature Medicine|July 1, 1996

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arraysM J Kozal, N Shah, N Shen, et al.

Journal of Virological Methods|December 1, 1987

Trifluorothymidine: potential non-invasive diagnosis of herpes simplex infection using 19F nuclear magnetic resonance in a murine hepatitis modelK H Rand, I Raad, A el Koussi, et al.

Blood|February 15, 1989

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferonS L Brown, R A Miller, S J Horning, et al.

Journal of Virology|May 1, 1987

Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responsesJ W Torseth, G H Cohen, R J Eisenberg, et al.

The Journal of Infectious Diseases|January 1, 1997

Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipientsL Rasmussen, C Hong, D Zipeto, et al.

Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)C M Gray, J Lawrence, J M Schapiro, et al.

The Journal of Infectious Diseases|June 1, 1996

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.

Pageof 30